Overview

A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This will be a single-center, randomized, parallel group, multiple dose administration, double-blind, placebo-controlled study to evaluate the effects of YKP10811 on gastric, small bowel, and colonic transit in patients with Chronic Constipation or Functional Constipation. Four groups including a placebo group will be enrolled and will receive multiple oral doses of YKP10811 or matching placebo.
Phase:
Phase 2
Details
Lead Sponsor:
SK Life Science
SK Life Science, Inc.